We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Over 90 percent of clinical trials evaluating targeted cancer therapies or immunotherapies fell short in reporting adverse events in their publications — specifically in reporting recurrent or late toxicities, and detailing the duration of adverse events — according to researchers who studied 81 trials related to FDA-approved solid tumor treatments. Read More
Novartis will pay more than $35 million to settle off-label promotion charges when the company marketed its eczema cream, Elidel, for use on infants. Read More